Measles, mumps, rubella vaccine (Priorix™; GSK-MMR): A review of its use in the prevention of measles, mumps and rubella

Drugs

Volumn 63, Issue 19, 2003, Pages 2107-2126

  Wellington, Keri ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Children; Immunisation; Measles; Measles mumps rubella vaccine; MMR; Mumps; Rubella

Indexed keywords

CHICKENPOX VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MMR; TRIPLE VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY PRODUCTION; ANTIBODY TITER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EDEMA; ERYTHEMA; EVALUATION; FEBRILE CONVULSION; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION PAIN; INJECTION SITE; MEASLES; MUMPS; PAROTITIS; PHOTOPHOBIA; PRIMARY PREVENTION; REVIEW; RUBELLA; SECONDARY PREVENTION; SEROCONVERSION; TORTICOLLIS; VACCINATION; VIRUS STRAIN; VOMITING;

CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; RUBELLA;

EID: 0141996194     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363190-00012     Document Type: Review

References (76)

1. Strebel P, Cochi S, Grabowsky M, et al. The unfinished measles immunization agenda. J Infect Dis 2003 May 15; 187 Suppl. 1: S1-7
2. World Health Organization. Global measles mortality reduction and regional elimination, 2000-2001. Wkly Epidemiol Rec 2002 Feb 15; 77 (7): 50-5
3. World Health Organization. WHO-UNICEF joint statement on strategies to reduce measles mortality worldwide. Wkly Epidemiol Rec 2002 Jul 5; 77 (27): 224-8
4. Koranyi K. Measles (rubeola). In: Rakel RE, Bope ET, editors. Conn's current therapy. Philadelphia (PA): W.B. Saunders Company, 2002: 134-6
5. Gershon A. Mumps. In: Braunwald E, Fauci AS, Kasper DL, et al, editors. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001: 1147-8
6. Shope TC. Mumps. In: Rakel RE, Bope ET, editors. Conn's current therapy. Philadelphia (PA): W.B. Saunders Company, 2002: 113-4
7. Gershon A. Rubella (German measles). In: Braunwald E, Fauci AS, Kasper DL, et al, editors. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001: 1145-7
8. Gabutti G, Rota MC, Salmaso S, et al. Epidemiology of measles, mumps and rubella in Italy. Epidemiol Infect 2002; 129 (3): 543-50
9. de Quadros CA, Olivé JM, Hersh BS, et al. Measles elimination in the Americas: evolving strategies. JAMA 1996 Jan 17; 275 (3): 224-9
10. Cutts FT, Henao-Restrepo A-M, Olivé JM. Measles elimination: progress and challenges. Vaccine 1999 Oct 29; 17 Suppl. 3: S47-52
11. Paget WJ, Zimmermann H, Vorkauf H. A national measles epidemic in Switzerland in 1997: consequences for the elimination of measles by the year 2007. Euro Surveill 2000 Feb; 5 (2): 17-20
12. GlaxoSmithKine Biologicals. Priorix: combined measles, mumps and rubella vaccine product monograph. Abingdon: TMG Heathcare Communications Ltd, 2002
13. Bernstein HH, Marchant C, Rathfon H, et al. Safety and immunogenicity of a new, live, attenuated combined measles, mumps and rubella vaccine in healthy U.S. children 12 to 18 months of age [abstract no. 1086]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, CA, 720
14. Crovari P, Gabutti G, Giammanco G, et al. Reactogenicity and immunogenicity of a new combined measles-mumps- rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines. Vaccine 2000 Jun 15; 18 (25): 2796-803
15. Gatchalian S, Cordero-Yap L, Lu-Fong M, et al. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. Southeast Asian J Trop Med Public Health 1999 Sep; 30 (3): 511-7
16. Lee C-Y, Tang R-B, Huang F-Y, et al. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children. Int J Infect Dis 2002; 6 (3): 202-9
17. Usonis V, Bakasenas V, Chitour K, et al. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children. Infection 1998; 26 (4): 222-6
18. Usonis V, Bakasenas V, Kaufhold A, et al. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J 1999 Jan; 18 (1): 42-8
19. Nolan T, McIntyre P, Roberton D, et al. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002 Dec 13; 21 (3-4): 281-9
20. Stück B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol 2002 Jun; 20 (2): 113-20
21. Arguedas A, Riccheimer R, Rocha C, et al. A randomized comparative study of a new measles, mumps and rubella (MMR) vaccine with a widely used MMR vaccine administered as a second dose at 4-6 years of age [abstract no. p-37 plus poster]. 18th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2000 May 3-5; Noordwijk, The Netherlands
22. Gothefors L, Bergström E, Bäckman M. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis 2001; 33 (7): 545-9
23. Usonis V, Bakasenas V, Denis M. Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385. Infection 2001 May-2001 30; 29 (3): 159-62
24. Ipp M, Cohen E, Goldbach M, et al. MMR vaccination at 12 months of age [abstract no. P30]. Proceedings of the 5th Canadian National Immunization Conference; 2002 Dec 1-3; Victoria, British Columbia. 143-4
25. Ipp M, Cohen E, Goldbach M, et al. Pain response to two licensed measles-mumps-rubella (MMR) vaccines in pre-school children: a randomized comparative study [abstract no. 900]. Presented at the Annual Meeting of the Pediatric Academic Societies; 2002 May 4-7; Baltimore, Maryland
26. Wood C, Bourrillon A, Barberousse C, et al. Self-assessment of immediate post-vaccination pain after administration of Priorix versus MMRII as a second dose in 4- to 6-year-old children [abstract no. 7.00]. 21st Annual Meeting of the European Society for Paediatric Infectious Diseases; 2003 Apr 9-11; Taormina, Sicily
27. Schlipköter U, Mühlberger N, von Kries R, et al. Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany. Infection 2002 Dec; 30 (6): 351-5
28. GlaxoSmithKline. Priorix: summary of product characteristics [online]. Available from URL: http:\uk.gsk.com [Accessed 2003 Apr 9]
29. British Medical Association and the Royal Pharmaceutical Society of Great Britain. MMR vaccine. British National Formulary. 43 ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2002
30. Robert Koch-Institute. Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut [online]. Available from URL: http://www.rki.de [Accessed 2003 Aug 7]
31. World Health Organization. Progress in reducing global measles deaths. Wkly Epidemiol Rec 2003 May 23; 78 (21): 184-7
32. Muscat M, Glismann S. Bang H. Measles in Europe in 2001-2003. Euro Surveill 2003 Jun; 8 (6): 123-9
33. Ciofi degli Atti ML, D'Argenio P, di Giorgio G, et al. Measles in Italy 2002: studies show correlation between vaccine coverage and incidence. Eurosurveillance Weekly 2002 Dec 5; 6 (49): 5-8
34. Siedler A, Hermann M, Schmitt H-J, et al. Consequences of delayed measles vaccination in Germany. Pediatr Infect Dis J 2002; 21 (9): 826-30
35. World Health Organization. Vaccines, immunization and biologicals: immunization Profile - Germany [online]. Available from URL: http://www.who.int/vaccines/GlobalSummary/Immunization/ [Accessed 2003 Aug 7]
36. Impfausschusses des Obersten Sanitätsrates. Impfplan 2003 Österreich [online]. Available from URL: http://www.gesundheit.bmsg.gv.at/ [Accessed 2003 Aug 7]
37. Dippelhofer A, Meyer C, Kamtsiuris P, et al. Erste Ergebnisse zum impfstatus aus der pilotphase des kinder- und jugendgesundheitssurveys [in German]. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 2002; 45: 332-7
38. World Health Organization. Vaccines, immunization and biologicals: measles vaccine [online]. Available from URL: http:// www.who.int/vaccines/en/measles.shtml [Accessed 2003 Apr 10]
39. World Health Organization. Measles Technical Working Group: strategies for measles control and elimination [online]. Available from URL: www.who.int/vaccines-documents [Accessed 2003 Apr 11]
40. World Health Organization. Vaccines, immunization and biologicals: mumps vaccine [online]. Available from URL: http://www.who.int/vaccines/en/mumps. shtml [Accessed 2003 Apr 10]
41. World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec 2001 Nov 9; 76 (45): 346-55
42. World Health Organization. Vaccines, immunization and biologicals: rubella vaccine [online]. Available from URL: http://www.who.int/vaccines/en/rubella.shtml [Accessed 2003 Apr 10]
43. Carter H, Campbell H. Rational use of measles, mumps and rubella (MMR) vaccine. Drugs 1993 May; 45 (5): 677-83
44. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999; 77 (1): 3-14
45. Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998 May 22; 47 (RR-8): 1-57
46. World Health Organization. Vaccines, Immunization and biologicals: adverse events following measles, mumps and rubella vaccine [online]. Available from URL: http://www.who.int/ vaccines-diseases/safety/infobank/mmr.shtml [Accessed 2003 Apr 11]
47. Martinez F, Sanchez C, Gonzalez L, et al. Two outbreaks of mumps in children vaccinated with the Rubini strain in Spain indicate low vaccine efficacy. Euro Surveill 2000 Jul; 5 (7): 80-4
48. Benevento and Compobasso Pediatricians Network for the Control of Vaccine-Preventable Diseases. Field evaluation of the clinical effectiveness of vaccines against pertussis, measles, rubella and mumps. Vaccine 1998 May; 16 (8): 818-22
49. Ki M, Park T, Yi SG, et al. Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. Am J Epidemiol 2003 Jan 15; 157 (2): 158-65
50. da Cunha SS, Rodrigues LC, Barreto ML, et al. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine 2002 Jan 15; 20 (7-8): 1106-12
51. da Silveira CM, Kmetzsch CI, Mohrdieck R, et al. The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps- rubella vaccine, Rio Grande do Sul, Brazil, 1997. Int J Epidemiol 2002 Oct: 31 (5): 978-82
52. Dourado I, Cunha S, Teixeira MG, et al. Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. Am J Epidemiol 2000 Mar 1; 151 (5): 524-30
53. Two MMR vaccines withdrawn after adverse reactions. Pharm J 1992 Sep 19; 249: 358
54. Shinefield HR, Black SB, Staehle BO, et al. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J 2002 Jun; 21 (6): 555-61
55. Ramsay MEB, Moffatt D, O'Connor M. Measles vaccine: a 27-year follow-up. Epidemiol Infect 1994 Apr; 112 (2): 409-12
56. Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993 Apr 17; 341 (8851): 979-82
57. Wakefield AJ, Pittilo RM, Sim R, et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993 Apr; 39 (4): 345-53
58. Wakefield AJ, Montgomery SM. Measles, mumps, rubella vaccine: through a glass, darkly. Adverse Drug React Toxicol Rev 2000 Dec; 19 (4): 265-83: discussion 284-92
59. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998 Feb 28; 351 (9103): 637-41
60. Kastner JL, Gellin BG. Measles-mumps-rubella vaccine and autism: the rise (and fall?) of a hypothesis. Pediatr Ann 2001 Jul; 30 (7): 408-15
61. Clements CJ, Ratzan S. Misled and confused? Telling the public about MMR vaccine safety. J Med Ethics 2003 Feb; 29 (I): 22-6
62. Stratton K, Gable A, Shetty P, et al. Immunization safety review: measles-mumps-rubella vaccine and autism. Washington, DC: National Academy Press, 2001
63. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001 Jun 14; 19: 3632-5
64. Taylor B, Miller E, Lingam R, et al. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002 Feb 16; 324: 393-6
65. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999 Jun 12; 353 (9169): 2026-9
66. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002 Nov 7; 347: 1477-82
67. Davis RL, Kramarz P, Bohlke K, et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Arch Pediatr Adolesc Med 2001 Mar; 155 (3): 354-9
68. Dales L, Hammer SJ, Smith NJ. MMR immunization and autism (reply). JAMA 2001 Jun 13; 285: 2852-3
69. Peltola H, Patja A, Leinikki P, et al. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study [letter]. Lancet 1998 May 2; 351 (9112): 1327-8
70. Makelä A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002 Nov; 110: 957-63
71. Patja A, Davidkin I, Kurki T, et al. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J 2000 Dec; 19: 1127-34
72. Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 2001 Oct; 108: e58
73. Kaye JA, del Mar Melero-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001 Feb 24; 322 (7284): 460-3
74. Christie B. Scottish expert group finds no link between MMR and autism. BMJ 2002 May 11; 324: 2
75. Lingam R, Simmons A, Andrews N, et al. Prevalence of autism and parentally reported triggers in a north east London population. Arch Dis Child 2003 Aug; 88 (8): 666-70
76. Wilson K, Mills E, Ross C, et al. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Arch Pediatr Adolesc Med 2003 Jul; 157 (7): 628-34